UY36967A - Tratamiento de la oligo-ovulación relacionada con esteatosis hepática - Google Patents

Tratamiento de la oligo-ovulación relacionada con esteatosis hepática

Info

Publication number
UY36967A
UY36967A UY0001036967A UY36967A UY36967A UY 36967 A UY36967 A UY 36967A UY 0001036967 A UY0001036967 A UY 0001036967A UY 36967 A UY36967 A UY 36967A UY 36967 A UY36967 A UY 36967A
Authority
UY
Uruguay
Prior art keywords
treatment
esteatosis
oligo
hepatic
ovulation
Prior art date
Application number
UY0001036967A
Other languages
English (en)
Inventor
De Zegher Francis
Ibañez Lourdes
Original Assignee
Katholieke Univ Leuven K U Leuven Res & Dev
Hospital Sant Joan De Déu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Univ Leuven K U Leuven Res & Dev, Hospital Sant Joan De Déu filed Critical Katholieke Univ Leuven K U Leuven Res & Dev
Publication of UY36967A publication Critical patent/UY36967A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método y a una composición para su uso en el tratamiento de una condición que se beneficia de la reducción de grasa hepática y/o visceral, como el síndrome de ovario poliquístico en chicas adolescentes o en mujeres en edad de procrear e implica el uso de espironolactona, pioglitazona y metformina.
UY0001036967A 2015-10-27 2016-10-27 Tratamiento de la oligo-ovulación relacionada con esteatosis hepática UY36967A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1518979.8A GB201518979D0 (en) 2015-10-27 2015-10-27 Treatment of hepatic steatosis related oligo-ovulation

Publications (1)

Publication Number Publication Date
UY36967A true UY36967A (es) 2017-05-31

Family

ID=55130283

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036967A UY36967A (es) 2015-10-27 2016-10-27 Tratamiento de la oligo-ovulación relacionada con esteatosis hepática

Country Status (24)

Country Link
US (2) US20190060328A1 (es)
EP (2) EP3892281A3 (es)
JP (2) JP6999903B2 (es)
KR (1) KR102608158B1 (es)
CN (2) CN117379440A (es)
AR (1) AR106505A1 (es)
AU (1) AU2016344737C1 (es)
BR (1) BR112018008496A2 (es)
CA (1) CA3003076C (es)
DK (1) DK3368044T3 (es)
ES (1) ES2883282T3 (es)
GB (1) GB201518979D0 (es)
HU (1) HUE055778T2 (es)
IL (1) IL258876B (es)
LT (1) LT3368044T (es)
MA (2) MA54412A (es)
MX (2) MX2018005252A (es)
PL (1) PL3368044T3 (es)
RS (1) RS62764B1 (es)
RU (1) RU2745606C2 (es)
SI (1) SI3368044T1 (es)
TW (1) TWI791420B (es)
UY (1) UY36967A (es)
WO (1) WO2017072243A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126329A1 (en) 2017-12-19 2019-06-27 Akouos Llc Aav-mediated delivery of therapeutic antibodies to the inner ear
MX2021001145A (es) * 2018-08-02 2021-06-23 Sant Joan De Deu Hospital Formulación de liberación inmediata de una combinación triple de principios activos farmacéuticos, útil en el tratamiento del síndrome del ovario poliquístico.
EP3842803A1 (en) * 2019-12-23 2021-06-30 Katholieke Universiteit Leuven Cxcl14 in polycystic ovary syndrome
CN116801911A (zh) 2020-05-13 2023-09-22 阿库斯股份有限公司 用于治疗slc26a4相关听力损失的组合物和方法
JP2023551533A (ja) 2020-12-01 2023-12-08 アコーオス インコーポレイテッド 前庭神経鞘腫関連症状を治療するための抗ｖｅｇｆ抗体構築物及び関連する方法
KR20230127263A (ko) 2020-12-29 2023-08-31 아카우오스, 인크. Clrn1-연관된 청력손실 및/또는 시력손실을 치료하기위한 조성물 및 방법
TW202342525A (zh) 2022-02-02 2023-11-01 美商阿科奧斯公司 用於治療前庭神經鞘瘤相關症狀之抗ｖｅｇｆ抗體構築體及相關方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
EP1267850B1 (en) * 2000-02-23 2007-04-11 Orentreich Foundation for the Advancement of Science, Inc. Use of insulin sensitivity increasing substances for the treatment of alopecia
GB0106565D0 (en) * 2001-03-16 2001-05-09 Leuven K U Res & Dev Growth hormone treatment
GB0108863D0 (en) * 2001-04-10 2001-05-30 Leuven K U Res & Dev Combinational therapy
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2004052390A1 (en) * 2002-12-11 2004-06-24 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
GB0702537D0 (en) 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
US10474539B1 (en) * 2015-12-18 2019-11-12 EMC IP Holding Company LLC Browsing federated backups
MX2021001145A (es) * 2018-08-02 2021-06-23 Sant Joan De Deu Hospital Formulación de liberación inmediata de una combinación triple de principios activos farmacéuticos, útil en el tratamiento del síndrome del ovario poliquístico.

Also Published As

Publication number Publication date
HUE055778T2 (hu) 2021-12-28
CA3003076C (en) 2023-12-05
GB201518979D0 (en) 2015-12-09
CA3003076A1 (en) 2017-05-04
MA54412A (fr) 2021-11-10
LT3368044T (lt) 2021-10-25
AU2016344737A1 (en) 2018-05-17
CN117379440A (zh) 2024-01-12
ES2883282T3 (es) 2021-12-07
RU2018119146A (ru) 2019-11-28
EP3368044A1 (en) 2018-09-05
PL3368044T3 (pl) 2021-12-20
WO2017072243A8 (en) 2018-03-22
MA43106A (fr) 2021-05-05
EP3892281A3 (en) 2021-11-10
MX2018005252A (es) 2018-09-18
JP2019501113A (ja) 2019-01-17
CN108778285A (zh) 2018-11-09
KR102608158B1 (ko) 2023-11-29
TW201720432A (zh) 2017-06-16
BR112018008496A2 (pt) 2018-10-23
RS62764B1 (sr) 2022-01-31
IL258876A (en) 2018-06-28
TWI791420B (zh) 2023-02-11
AU2016344737C1 (en) 2021-10-07
RU2745606C2 (ru) 2021-03-29
KR20180098234A (ko) 2018-09-03
WO2017072243A1 (en) 2017-05-04
IL258876B (en) 2022-03-01
EP3368044B1 (en) 2021-06-09
MA43106B1 (fr) 2021-09-30
SI3368044T1 (sl) 2022-05-31
US20240000804A1 (en) 2024-01-04
AR106505A1 (es) 2018-01-24
EP3892281A2 (en) 2021-10-13
AU2016344737A9 (en) 2018-08-09
DK3368044T3 (da) 2021-09-13
JP6999903B2 (ja) 2022-02-04
WO2017072243A9 (en) 2018-07-26
MX2021007976A (es) 2021-08-16
US20190060328A1 (en) 2019-02-28
RU2018119146A3 (es) 2020-02-25
AU2016344737B2 (en) 2021-07-08
JP2022009374A (ja) 2022-01-14

Similar Documents

Publication Publication Date Title
UY36967A (es) Tratamiento de la oligo-ovulación relacionada con esteatosis hepática
IL261629B1 (en) Cannobinoid compounds are rich in terpenes
BR112017020491A2 (pt) composições e métodos para distribuição de agentes de biomacromolécula.
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
BR112017027332A2 (pt) composições tópicas que compreendem um corticosteróide e um retinóide para tratar psoríase.
BR112017021665A2 (pt) composições de conservantes sinérgicos.
DK3753929T3 (da) Dimere kontrastmidler
ITUB20153129A1 (it) Composizione elastomerica comprendente grafene e componenti di pneumatico comprendenti detta composizione.
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
KR20180084853A (ko) 지혈 조성물
ECSP19090645A (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta
BR112017015946A2 (pt) composições de oligossacarídeo para uso como ingredientes alimentares e métodos para produzir as mesmas
AR102790A1 (es) Composiciones antimicrobianas y métodos relacionados para tratar productos alimenticios y superficies
PL3364947T3 (pl) Wodna kompozycja zawierająca dantrolen
ZA201907874B (en) Skin composition booster oil
CL2018003792A1 (es) Procedimiento para enfriamineto de elementos de madera acetilada.
CL2018001788A1 (es) Composiciones y métodos para evaluar el riesgo de ocurrencia de cáncer.
CL2016000351A1 (es) Método para la cuantificación de actinio-227 en composiciones de radio-223.
BR112016024879A2 (pt) inibidor de vulcanização prematura de poliuretana
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
GB201721340D0 (en) Tanning Composition
IT201700016964A1 (it) Composizione per la tosse
DK3357520T3 (da) Viskoelastisk sammensætning
PL3216452T3 (pl) Kompozycja do zapobiegania lub leczenia zapalenia błony śluzowej zawierająca jako skuteczny składnik NecroX
BR112017017987A2 (pt) composições incluindo um nanocompósito de (ve)-zno projetado para vacância, métodos de fabricação das composições e métodos de uso das composições